Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists, androgen deprivation therapy and anti-androgen receptor therapy
AssigneeThe University of Chicago
InventorsRussell Z. Szmulewitz, Suzanne D. Conzen
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
Claims13
A method of treating prostate cancer in a subject comprising co-administering to said subject a glucocorticoid receptor (GR) antagonist and a drug or treatment that decreases circulating levels of testosterone (androgen deprivation therapy), wherein said subject exhibits androgen-deprived prostate cancer, and wherein said subject has previously been or is being treated with androgen deprivation therapy, wherein said androgen deprivation therapy comprises treatment with leuprolide, goserelin, triptorelin, histrelin degerelix or surgical castration, and wherein said subject has been or is being treated with an androgen receptor (AR) antagonist.
Dependencies are inferred from the claim text.